RAMP2 and pancreatic neoplasm: Thus, a cocktail of antibodies directed against CLR and RAMP2/3 exerted an antitumor effect against glioblastoma, mesothelioma, and lung and colon cancer, and peptide antagonists such as AM22–52 also showed an antitumor action against melanoma, mesothelioma, and renal, ovarian, breast and pancreatic cancer [217,350,354].